- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00964236
The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
January 2, 2018 updated by: Shawn Christ, University of Missouri-Columbia
The objective of the study is to determine whether Kuvan™ (sapropterin) improves the strength of the functional connectivity between brain regions in individuals with PKU.
Study Overview
Detailed Description
The proposed study is designed to evaluate the hypothesis that functional connectivity may represent an early marker for neurocognitive improvements related to Kuvan treatment.
As a first step in the study, 20 patients with PKU who are ≥ 6 years of age will receive baseline functional connectivity magnetic resonance imaging (fcMRI) evaluations before being treated with Kuvan™.
Response to Kuvan™ will be monitored for 4 weeks.
At the end of 4 weeks, response to Kuvan™ will be reviewed and all 20 patients will receive follow-up fcMRI evaluations.
Fifteen patients with a reduction of ≥ 20% in blood phenylalanine will continue in the study and receive a third fcMRI evaluation at the end of 6 months of treatment with Kuvan™.
For comparison purposes and to control for possible practice effects in repeated testing, a matched control group of 20 healthy individuals without PKU will used.
All 20 of the control subjects will receive baseline and 4-week fcMRI evaluations; fifteen will receive a 6-month evaluation.
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65211
- University of Missouri
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Primary care clinic for phenylketonuria.
Columbia, Missouri, community for control.
Description
Inclusion Criteria:
- Willing and able to provide informed consent or assent.
- Willing and able to comply with study procedures.
- Greater than or equal to 6 years of age.
- For phenylketonuria, intention of physician to prescribe sapropterin.
- For phenylketonuria, phenylalanine level greater than or equal to 300μmol/L.
- For phenylketonuria, negative pregnancy test if of childbearing potential.
- For phenylketonuria, willing to use contraception if sexually active.
Exclusion Criteria:
- Pregnant, breastfeeding, or planning to become pregnant during study.
- Use of investigational product less than 30 days prior to or during study.
- Concurrent condition that could interfere with participation or safety.
- Any condition creating high risk of poor compliance with study.
- Perceived to be unreliable or unavailable for study.
- Use of L-Dopa, methotrexate, or other drugs that inhibit folate metabolism.
- For phenylketonuria, known hypersensitivity to sapropterin or excipients.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Control
Healthy individuals without phenylketonuria (PKU).
|
|
Sapropterin
Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
|
Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
functional magnetic resonance imaging of the brain
Time Frame: baseline, 4 week, & 6 month follow-up
|
baseline, 4 week, & 6 month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Shawn E Christ, Ph.D., University of Missouri-Columbia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Christ SE, Steiner RD, Grange DK, Abrams RA, White DA. Inhibitory control in children with phenylketonuria. Dev Neuropsychol. 2006;30(3):845-64. doi: 10.1207/s15326942dn3003_5.
- Araujo GC, Christ SE, Steiner RD, Grange DK, Nardos B, McKinstry RC, White DA. Response monitoring in children with phenylketonuria. Neuropsychology. 2009 Jan;23(1):130-4. doi: 10.1037/a0013488.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
August 1, 2010
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
August 21, 2009
First Submitted That Met QC Criteria
August 21, 2009
First Posted (Estimate)
August 24, 2009
Study Record Updates
Last Update Posted (Actual)
January 4, 2018
Last Update Submitted That Met QC Criteria
January 2, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKU/Kuvan/Christ
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phenylketonuria
-
Vitaflo International, LtdUniversity College London HospitalsRecruiting
-
BioMarin PharmaceuticalRecruitingPhenylketonuria (PKU)United States, Germany, Italy
-
Nutricia ResearchCompleted
-
BioMarin PharmaceuticalActive, not recruiting
-
BioMarin PharmaceuticalCompletedPhenylketonuria (PKU)United States, Turkey, Canada, France, Germany, Italy, United Kingdom
-
Washington University School of MedicineUniversity of Missouri-Columbia; Northwestern University; Oregon Health and Science... and other collaboratorsTerminated
-
BioMarin PharmaceuticalRecruitingPhenylketonuria (PKU)United States
-
University of Southern CaliforniaBioMarin PharmaceuticalCompleted
-
Stanford UniversityBioMarin PharmaceuticalWithdrawnClassical Phenylketonuria(PKU)
-
BioMarin PharmaceuticalActive, not recruitingPhenylketonuria (PKU)United States, Germany
Clinical Trials on Sapropterin
-
University of California, San DiegoBioMarin PharmaceuticalWithdrawnBehavioral Manifestations of Lesch-Nyhan DiseaseUnited States
-
University of UtahBioMarin PharmaceuticalCompletedGTP Cyclohydrolase DeficiencyUnited States
-
Washington University School of MedicineUniversity of Missouri-Columbia; Northwestern University; Oregon Health and Science... and other collaboratorsTerminated
-
BioMarin PharmaceuticalTerminatedPhenylketonuriaItaly, Switzerland
-
The University of Texas Health Science Center,...BioMarin PharmaceuticalTerminatedPhenylketonuria | HyperphenylalaninemiaUnited States
-
Universidade do PortoBioMarin Pharmaceutical; Centro Hospitalar do PortoCompleted
-
Providence VA Medical CenterBioMarin Pharmaceutical; LifespanCompletedHeart Failure | Cardiovascular DiseaseUnited States
-
Washington University School of MedicineUniversity of Missouri-Columbia; BioMarin PharmaceuticalCompleted
-
The Children's Health CouncilBioMarin PharmaceuticalCompleted
-
Fundacion Clinic per a la Recerca BiomédicaCompletedLiver Cirrhosis | Portal HypertensionSpain